basal cell carcinoma

[Histopathology] Investigators provide a comprehensive overview and update of the molecular findings associated with adnexal tumors of the skin.

[MediWound Ltd.] MediWound Ltd. announced the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer.

[Nature Communications] Researchers identified a critical requirement of B-plexin transmembrane receptors in the response to crowding-induced mechanical forces during embryonic skin development.

[Sirnaomics, Inc.] Sirnaomics, Inc. announced dose administration for the first patient in a Phase IIa clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.

[AiViva Biopharma] AiViva Biopharma Inc announced that it had begun dosing patients diagnosed with superficial or nodular basal cell carcinoma with AIV001. AIV001 is AiViva’s novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions.